Henry Schein ( HSIC ) is acquiring a 60% stake in dental implant manufacturer BioHorizons. The deal calls for an equity investment by HSIC
thanks to pent-up demand, in our view. However, Patterson's growth continues to that of its main competitor, Henry Schein , in the U.S. dental market, which also suggests Patterson might be yielding potential market share gains from smaller
Henry Schein ( HSIC ): FQ3 EPS of $1.23 beats by $0.02 . Revenue of $2.3B (+5.3% Y/Y) misses by $0.07B . ( PR ) Post your comment!
We don’t plan to change our $99 fair value estimate for Henry Schein , as the company remains on track to meet our year-end expectations after its third-quarter results. Additionally, our 2014
We have upgraded Henry Schein HSIC and Patterson Companies PDCO to wide-moat companies thanks to their strong competitive advantages in the dental and veterinary
We have upgraded Henry Schein HSIC and Patterson PDCO to wide-moat companies thanks to their strong competitive advantages in the dental and veterinary distribution
long-term shareholder interests. Henry Schein distributes health care products ..... operating and financial risk at Henry Schein is limited. Schein's scale helps ..... medical distribution segment. Henry Schein possesses attractive health care
We plan to raise our fair value estimate for Henry Schein HSIC as we transfer coverage to a new analyst. In the first quarter, Schein reported 9.3% revenue growth, which includes
integration features that VetStreet may not have. With VCA Antech and Idexx aggressively pushing their pet owner portals, we think the smaller portals offered by vet distributors like Henry Schein HSIC and Patterson PDCO could get squeezed out.
Henry Schein HSIC realized organic constant-currency growth of 4.5% during the third quarter, which is on par with previous results